根据周一在美国糖尿病协会年度会议上公布的二期试验结果，阿斯利康的实验性GLP-1口服药在为期36周的治疗中，使肥胖患者的体重平均降低了近12%。同时，该药物将糖尿病患者的糖化血红蛋白水平——一项衡量血糖的关键指标——平均降低了1.9个百分点。
此项研究成果同步发表于《柳叶刀》杂志。这是这家英国制药巨头更广泛战略的一部分，其目标直指糖尿病、心脏病、肾衰竭及肝病，而非仅仅是美容减重。该公司押注于，随着减肥药物报销政策收紧，针对特定疾病的治疗将能继续获得保险支付方的支持。
阿斯利康首席执行官苏博科在一次采访中表示：“支付方，也就是最终买单的雇主们，开始思考，‘我希望人们健康，但未必愿意为那些只想在今年夏天去海滩前更好看的人付费。’我们想要向支付方证明，我们的药物能帮助各类患者。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.